Barinthus Biotherapeutics plc
BRNS
$0.7815
-$0.0415-5.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -88.71% | 152.82% | -50.83% | 13.68% | -94.99% |
| Gross Profit | 88.71% | 1,853.75% | 27.13% | -19.61% | 89.33% |
| SG&A Expenses | -124.73% | 1,045.06% | -45.15% | -48.96% | -33.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -86.30% | 59.26% | -32.62% | -20.56% | -40.06% |
| Operating Income | 86.30% | 39.58% | 31.75% | 18.73% | 25.19% |
| Income Before Tax | -13.68% | 44.73% | 32.09% | 16.98% | 21.88% |
| Income Tax Expenses | 100.37% | 99.50% | 99.38% | 92.83% | 59.39% |
| Earnings from Continuing Operations | -19.09% | 42.39% | 28.88% | 14.83% | 18.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1,800.00% | -60.53% | -45.45% | -27.91% | 88.46% |
| Net Income | -18.78% | 42.34% | 28.87% | 14.80% | 18.39% |
| EBIT | 86.30% | 39.58% | 31.75% | 18.73% | 25.19% |
| EBITDA | 89.17% | 41.43% | 33.04% | 20.17% | 26.57% |
| EPS Basic | -14.12% | 43.65% | 30.01% | 16.48% | 20.99% |
| Normalized Basic EPS | 90.09% | 44.33% | 33.19% | 17.52% | 27.59% |
| EPS Diluted | -13.62% | 43.24% | 30.05% | 16.67% | 20.64% |
| Normalized Diluted EPS | 90.09% | 44.33% | 33.19% | 17.52% | 27.59% |
| Average Basic Shares Outstanding | 4.07% | 2.30% | 1.65% | 2.00% | 3.30% |
| Average Diluted Shares Outstanding | 4.07% | 2.30% | 1.65% | 2.00% | 3.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |